Results 101 to 110 of about 2,048,259 (212)

Association of Frailty With Transfusions, Hospitalizations, and Survival in Patients With Myelodysplastic Syndrome Initiating Hypomethylating Agents

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Prognostic scoring systems in MDS lack functional status measures. We sought to evaluate the influence of frailty on overall survival and care utilization in a national cohort. We conducted a retrospective study in the US Veterans Affairs Healthcare System of patients with MDS initiated on hypomethylating agents (HMAs) from 2004 ...
Anahid Hamparsumian, Jennifer La, Mayuri Dharne, Gary Gilbert, Mary T. Brophy, Nhan V. Do, Dae Hyun Kim, Jane A. Driver, Nathanael R. Fillmore, Clark DuMontier   +9 more
wiley   +1 more source

The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Objectives: To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower‐risk myelodysplastic syndromes. Methods: We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow‐up data in the prospective EUMDS study.
Dominic Culligan, Adele Taylor, Alexandra Smith, Catherine Cargo, Howard Oster, Argiris Symeonidis, Reinhard Stauder, Saskia Langemeijer, Luca Malcovati, Pierre Fenaux, Jaroslav Čermák, Eva Hellström‐Lindberg, Juliet Mills, Ioannis Kotsianidis, Maud D'Aveni, Corine van Marrewijk, Marlijn Hoeks, Theo de Witte, David Bowen, Moshe Mittelman   +19 more
wiley   +1 more source

Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations

Hematology Reports, 2016
Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a hematologic malignancy that often results in transfusion dependency and a hypercoagulable state.
Ryan Keen, Jeremy Pantin, Natasha Savage, Paul M. Dainer   +3 more
doaj   +1 more source

Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis

, 2010
Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.
Rosati, Stefano, de Wolf, Joost T. M., van de Loosdrecht, Arjan A., Mulder, Andre B., Vellenga, Edo, Huls, Gerwin   +5 more
core   +1 more source

Refractory Anemia with Ring Sideroblasts (RARS) and RARS with Thrombocytosis (RARS-T) – “2017 Update on Diagnosis, Risk-stratification, and Management”

American journal of hematology/oncology, 2017
Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic ...
M. Patnaik, A. Tefferi
semanticscholar   +1 more source

Clinical and Morphological Bone Marrow Characteristics of Pearson Syndrome: About Three Consecutive Cases and Review of the Literature

Case Reports in Pediatrics
Pearson syndrome (PS) is a rare and fatal multisystem disorder caused by a mitochondrial DNA (mtDNA) deletion. Most patients develop refractory anemia in early infancy, rapidly followed by multiple complications such as failure to thrive, muscle ...
Gaetan-Nagim Degroot, Aurélie Empain, Laurence Dedeken, Anne Demulder, Laurence Rozen   +4 more
doaj   +1 more source

Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. [PDF]

, 2016
Heterozygous somatic mutations affecting the spliceosome gene SF3B1 drive age-related clonal hematopoiesis, myelodysplastic syndromes (MDS) and other neoplasms. To study their role in such disorders, we generated knock-in mice with hematopoietic-specific
Campbell, P.C, Manes, N, Y Yang, S Pacharne, G S Vassiliou, Iorio, F, Tzelepis, K, M Seiler, Seiler, M, Kent, David Geoffrey, A Mupo, P C Campbell, Sathiaseelan, V, Buonamici, S, Vassiliou, G.S, Agrawal, AA, N Bolli, V Sathiaseelan, Mupo, A, A Pance, P Wright, E Papaemmanuil, Papaemmanuil, Elli, Yang, Y, F Iorio, K Tzelepis, D G Kent, Bolli, N, S Buonamici, R Bautista, N Manes, Bautista, R, A A Agrawal, Pance, A, Pacharne, S, Wright, P, S. Buonamici, A. Mupo, A. A. Agrawal, P. Wright, V. Sathiaseelan, M. Seiler, N. Bolli, P. C. Campbell, K. Tzelepis, Y. Yang, E. Papaemmanuil, F. Iorio, R. Bautista, N. Manes, D. G. Kent, G. S. Vassiliou, S. Pacharne, A. Pance   +53 more
core   +2 more sources

Congenital sideroblastic anemia: A report of two cases

Indian Journal of Pathology and Microbiology, 2009
Sideroblastic anemia, comprising of acquired and congenital forms, is a heterogeneous group of disorders characterized by the presence of ring sideroblasts in the bone marrow. Congenital sideroblastic anemia is a rare condition which is mostly X-linked,
Gupta Sanjeev, Rao Seema, Kar Rakhee, Tyagi Seema, Pati Hara   +4 more
doaj  

Somatic RUNX1 exonic deletions in myelodysplastic syndrome: A rare yet high‐risk recurrent genetic aberration

HemaSphere, Volume 10, Issue 8, August 2026.
Ahmed Al‐Djaber, Albin Österroos, Alessandro Baldi, Arielle R. Munters, Nikolaj Juul Nitschke, Klas Raaschou‐Jensen, Claudia Schöllkopf, Marianne Tang Severinsen, Tatjana Pandzic, Manja Meggendorfer, Joachim Weischenfeldt, Anne Stidsholt Roug, Kirsten Grønbæk, Claes Ladenvall, Torsten Haferlach, Claudia Haferlach, Thale Kristin Olsen, Panagiotis Baliakas   +17 more
wiley   +1 more source

LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA

Leukemia Research Reports
Introduction: Luspatercept reduced the severity of anemia in transfusion-dependent lower risk MDS with ring sideroblasts (RS) in the MEDALIST trial. Here we present real-world data in a prospective multicenter registry study of MDS patients treated with ...
Y. Gong, L. Zhou, T. Zhang, D. Xu, Y. Zhang, J. Shi, J. Li, G. He   +7 more
doaj   +1 more source